Ebn Sina Medical, a subsidiary of Aamal Company Q.P.S.C. and a leading pharmaceutical supplier in Qatar, has strengthened its long-standing partnership with global healthcare leader Novo Nordisk by announcing the availability of Wegovy® (Semaglutide 2.4 mg) in the Qatari market. This milestone reflects a shared commitment to addressing the rising prevalence of obesity and its related health complications in Qatar.
The announcement was made during a high-level event attended by H.E. Mr. Anders Bjørn Hansen, Ambassador of Denmark to the UAE and Qatar; Mr. Rashid Al Mansoori, CEO of Aamal Company; Mr. Manvendra Singh, General Manager of Novo Nordisk Qatar; and Dr. Nayla Mansour, Commercial Director representing Ebn Sina Medical’s General Manager Mr. Essam Faragalla.
Wegovy®: A Transformative Solution for Obesity Management
Wegovy®, the first and only once-weekly GLP-1 receptor agonist (GLP-1RA) for chronic weight management, is now available for both adults and adolescents aged 12 and older in Qatar. The active ingredient, Semaglutide 2.4 mg, works by reducing appetite and increasing satiety, supporting meaningful weight loss and improved metabolic health when used alongside a reduced-calorie diet and increased physical activity.
Clinical trials have shown that Wegovy® can deliver an average of 17% weight loss sustained over two years, with one-third of patients achieving a 20% reduction in body weight. The SELECT trial, involving over 17,000 participants, also demonstrated a 20% reduction in the risk of major adverse cardiovascular events (MACE) in overweight or obese individuals with established cardiovascular disease but without type 2 diabetes.
Obesity: A Pressing Health Challenge in Qatar
With 41% of adults in Qatar classified as obese—a figure that rises to 46% among women—Qatar ranks among the countries with the highest obesity rates globally. In addition, nearly 76% of the population is considered overweight, a situation that is driving up rates of diabetes, pre-diabetes, and cardiovascular diseases. Among adolescents, approximately 20% are affected by obesity, highlighting the urgency of accessible and effective interventions.
Healthcare Leaders Speak Out
Mr. Rashid bin Ali Al Mansoori, CEO of Aamal Company, emphasized the importance of this development:
“This launch represents a major step forward in our strategy to enhance healthcare access and outcomes in Qatar. Through our subsidiaries like Ebn Sina Medical, we are fully aligned with the National Health Strategy and Qatar Vision 2030.”
Mr. Manvendra Singh, General Manager of Novo Nordisk Qatar, stated:
“We are proud to bring over a century of leadership in chronic disease management to Qatar. The availability of Wegovy® is a critical milestone in our efforts to treat obesity as a serious, chronic disease. Our partnership with Ebn Sina Medical is instrumental in this mission.”
Mr. Essam Faragalla, General Manager of Ebn Sina Medical, added:
“We are dedicated to providing access to the most advanced medical treatments. The introduction of Wegovy® reinforces our role as a trusted healthcare partner, and underlines our focus on patient-centric care and innovation.”
Prof. Usama Alalami, Head of Medical at Novo Nordisk Qatar, noted:
“Obesity is the main driver of Qatar’s diabetes epidemic, accounting for 57.5% of diabetes cases. Clinical data shows that 80% of prediabetic individuals using Semaglutide 2.4 mg reverted to normoglycemia, highlighting its preventive potential.”
About Ebn Sina Medical:
A subsidiary of Aamal Company Q.P.S.C., Ebn Sina Medical is one of Qatar’s premier providers of medical and pharmaceutical products, committed to delivering innovative solutions and improving public health outcomes.
About Novo Nordisk:
Novo Nordisk is a global leader in healthcare headquartered in Denmark, with more than 100 years of experience in driving change to defeat diabetes and other serious chronic diseases.
